Viemed Healthcare, Inc. (VMD) Key Metrics
VMD valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $361.1M
- Enterprise value
- $336.5M
- P/E (TTM)
- 26.3 10-yr median 26.1
- Forward P/E
- 18.3
- PEG ratio
- 1.84
- Price / sales
- 1.2 10-yr median 2.0
- Price / book
- 2.3 10-yr median 2.9
- EV / EBITDA
- 5.9 10-yr median 8.3
- Dividend yield
- —
- Beta
- 1.04
VMD key metrics, 2016–2025
Fiscal year ended December 31, 2025 · U.S. dollarsVMD valuation Price multiples at each fiscal year-end price.
VMD returns How much profit the business earns on the capital it uses.
VMD per-share figures Results divided by the shares outstanding at year-end.
VMD financial health Debt, liquidity and how easily interest is covered.
VMD efficiency & capital use Working capital cycle and where the cash goes.
VMD valuation history
VMD returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
VMD debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
VMD cash returned to shareholders
VMD price vs earnings per share
VMD key metrics
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $303.3M | $327.3M | $317.0M | $300.9M | $212.4M | $314.5M | $246.4M | $150.8M | — | — |
| Enterprise value | $305.8M | $316.6M | $314.5M | $284.7M | $190.5M | $294.6M | $252.6M | $143.8M | — | — |
| P/E ratio | 20.3 | 29.1 | 30.9 | 48.4 | 23.3 | 10.0 | 28.9 | 15.9 | — | — |
| Price / sales | 1.1 | 1.5 | 1.7 | 2.2 | 1.8 | 2.4 | 3.1 | 2.3 | — | — |
| Price / book | 2.1 | 2.5 | 2.8 | 3.1 | 2.2 | 3.8 | 5.6 | 4.3 | — | — |
| Price / free cash flow | 25.4 | 248.3 | 16.6 | 62.1 | 77.2 | 14.3 | 43.2 | 9.3 | — | — |
| Price / operating cash flow | 5.8 | 8.4 | 7.0 | 10.8 | 9.4 | 9.0 | 12.9 | 6.7 | — | — |
| EV / sales | 1.1 | 1.4 | 1.7 | 2.1 | 1.6 | 2.2 | 3.1 | 2.2 | — | — |
| EV / EBITDA | 5.9 | 7.5 | 8.6 | 11.5 | 7.9 | 8.1 | 16.3 | 10.3 | — | — |
| EV / free cash flow | 25.6 | 240.2 | 16.4 | 58.7 | 69.2 | 13.4 | 44.3 | 8.8 | — | — |
| Earnings yield | 4.9% | 3.4% | 3.2% | 2.1% | 4.3% | 10.0% | 3.5% | 6.3% | — | — |
| Free cash flow yield | 3.9% | 0.4% | 6.0% | 1.6% | 1.3% | 7.0% | 2.3% | 10.8% | — | — |
| Dividend yield | — | — | 0.1% | 0.1% | 0.1% | — | 0.2% | 0.0% | — | — |
| Shareholder yield (dividends + buybacks) | 4.4% | 0.3% | 0.3% | 3.3% | 0.7% | 0.0% | 0.8% | 1.1% | — | — |
| Share price at fiscal year-end | $7.43 | $8.02 | $7.85 | $7.56 | $5.22 | $7.76 | $6.20 | $3.80 | — | — |
| Per share | ||||||||||
| Revenue per share | $6.62 | $5.50 | $4.53 | $3.49 | $2.88 | $3.24 | $2.02 | $1.62 | $1.24 | $0.83 |
| Earnings per share | $0.37 | $0.28 | $0.25 | $0.16 | $0.22 | $0.78 | $0.21 | $0.24 | $0.22 | $0.03 |
| Operating cash flow per share | $1.27 | $0.96 | $1.12 | $0.70 | $0.55 | $0.87 | $0.48 | $0.56 | $0.32 | $0.17 |
| Free cash flow per share | $0.29 | $0.03 | $0.47 | $0.12 | $0.07 | $0.54 | $0.14 | $0.41 | $0.21 | $0.13 |
| Cash per share | $0.33 | $0.43 | $0.32 | $0.42 | $0.70 | $0.76 | $0.34 | $0.26 | $0.13 | $0.11 |
| Book value per share | $3.47 | $3.22 | $2.82 | $2.44 | $2.33 | $2.02 | $1.10 | $0.88 | $0.63 | $0.34 |
| Tangible book value per share | $1.99 | $2.39 | $2.07 | $2.44 | $2.33 | $2.02 | $1.10 | $0.88 | $0.63 | $0.34 |
| Dividends per share | — | — | $0.01 | $0.01 | $0.00 | — | $0.01 | $0.00 | $0.00 | $0.00 |
| Capex per share | $0.98 | $0.93 | $0.65 | $0.58 | $0.49 | $0.32 | $0.34 | $0.15 | $0.11 | $0.04 |
| Debt per share | $0.39 | $0.17 | $0.26 | $0.02 | $0.16 | $0.27 | $0.49 | $0.09 | $0.14 | $0.17 |
| Shares outstanding | 40.8M | 40.8M | 40.4M | 39.8M | 40.7M | 40.5M | 39.7M | 39.7M | 38.0M | 37.9M |
| Change in shares outstanding | +0.0% | +1.1% | +1.4% | −2.1% | +0.4% | +2.0% | +0.2% | +4.5% | +0.2% | — |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | 10.9% | 9.2% | 9.7% | 6.5% | 10.3% | 50.3% | 21.7% | 32.4% | 44.6% | 10.0% |
| Return on invested capital (ROIC) | 11.1% | 10.9% | 10.6% | 7.4% | 12.5% | 48.0% | 22.0% | 38.1% | 45.3% | 2.6% |
| Return on assets (ROA) | 7.6% | 6.8% | 7.5% | 5.3% | 7.9% | 32.3% | 12.5% | 20.8% | 26.2% | 5.2% |
| Return on tangible assets | 9.7% | 7.9% | 8.2% | 5.3% | 7.7% | 28.0% | 10.3% | 17.8% | 21.7% | 5.0% |
| Free cash flow margin | 4.4% | 0.6% | 10.4% | 3.5% | 2.4% | 16.8% | 7.1% | 25.2% | 17.1% | 15.1% |
| Income quality (OCF / net income) | 3.48 | 3.47 | 4.41 | 4.46 | 2.46 | 1.11 | 2.24 | 2.35 | 1.47 | 5.22 |
| Financial health | ||||||||||
| Total debt | $15.9M | $6.9M | $10.3M | $694,000 | $6.5M | $11.1M | $19.5M | $3.4M | $5.2M | $6.5M |
| Cash & short-term investments | $13.5M | $17.5M | $12.8M | $16.9M | $28.4M | $31.0M | $13.4M | $10.4M | $5.1M | $4.3M |
| Net debt | $2.4M | −$10.7M | −$2.5M | −$16.2M | −$21.9M | −$19.8M | $6.2M | −$7.0M | $81,000 | $2.2M |
| Debt / equity | 0.11 | 0.05 | 0.09 | 0.01 | 0.07 | 0.14 | 0.45 | 0.10 | 0.22 | 0.50 |
| Debt / assets | 0.07 | 0.04 | 0.07 | 0.01 | 0.06 | 0.10 | 0.24 | 0.06 | 0.14 | 0.26 |
| Net debt / EBITDA | 0.05 | −0.25 | −0.07 | −0.65 | −0.91 | −0.54 | 0.40 | −0.50 | 0.01 | 1.19 |
| Current ratio | 1.18 | 1.42 | 1.19 | 2.11 | 2.66 | 2.05 | 1.07 | 1.18 | 1.29 | 1.22 |
| Quick ratio | 1.06 | 1.30 | 1.05 | 1.92 | 2.52 | 1.95 | 1.02 | 1.03 | 1.17 | 1.04 |
| Interest coverage | 17.5 | 23.1 | 33.8 | 41.9 | 36.4 | 52.6 | 28.2 | 55.6 | 32.4 | 1.2 |
| Working capital | $7.4M | $15.6M | $6.2M | $20.9M | $29.5M | $24.2M | $1.9M | $3.5M | $3.9M | $2.0M |
| Invested capital | $144.0M | $120.7M | $111.4M | $80.9M | $72.9M | $61.8M | $49.9M | $28.0M | $23.8M | $15.0M |
| Tangible asset value | $83.3M | $99.5M | $83.6M | $97.1M | $94.8M | $81.7M | $43.7M | $32.4M | $23.7M | $12.9M |
| Net current asset value | −$22.9M | $9.1M | −$2.6M | $19.8M | $24.2M | $16.3M | −$11.1M | $2.0M | $3.1M | −$603,000 |
| Graham number | $5.34 | $4.47 | $4.01 | $2.93 | $3.43 | $5.94 | $2.30 | $2.18 | $1.74 | $0.50 |
| Graham net-net per share | −$0.89 | −$0.13 | −$0.30 | $0.26 | $0.43 | $0.26 | −$0.41 | −$0.07 | −$0.02 | −$0.08 |
| Capital allocation | ||||||||||
| Dividends paid | — | — | $434,120 | $271,786 | $111,014 | — | $405,206 | $0 | $0 | $0 |
| Share buybacks (net) | $13.2M | $1.1M | $594,000 | $9.7M | $1.4M | $0 | $1.5M | $1.6M | $0 | $0 |
| Dividend payout ratio | — | — | 4.2% | 4.4% | 1.2% | — | 4.8% | 0.0% | 0.0% | 0.0% |
| Dividends + buybacks / free cash flow | 110.8% | 81.1% | 5.4% | 205.8% | 56.2% | 0.0% | 33.8% | 9.8% | 0.0% | 0.0% |
| Capex / revenue | 14.8% | 16.8% | 14.3% | 16.5% | 16.9% | 9.9% | 16.7% | 9.5% | 8.5% | 5.3% |
| Capex / operating cash flow | 77.0% | 96.6% | 57.7% | 82.5% | 87.8% | 37.2% | 70.1% | 27.3% | 33.3% | 26.1% |
| Capex / depreciation | 1.40 | 1.49 | 1.19 | 1.47 | 1.75 | 1.36 | 2.09 | 1.62 | 1.57 | 1.18 |
| Stock-based compensation / revenue | 3.4% | 2.8% | 3.2% | 3.7% | 4.4% | 3.7% | 4.8% | 4.2% | 1.8% | — |
| R&D / revenue | 1.1% | 1.4% | 1.5% | 1.9% | 1.8% | 0.8% | 1.1% | 1.3% | 1.8% | 2.7% |
| SG&A / revenue | 48.3% | 50.2% | 51.5% | 52.8% | 51.3% | 44.0% | 56.4% | 57.8% | 43.1% | 43.9% |
| Efficiency | ||||||||||
| Days sales outstanding | 34.1 | 35.3 | 33.8 | 39.6 | 42.2 | 33.2 | 46.3 | 52.7 | 56.7 | 74.7 |
| Days of inventory on hand | 14.9 | 17.9 | 21.3 | 20.3 | 19.9 | 13.1 | 32.0 | 49.4 | 48.5 | 46.2 |
| Days payables outstanding | 34.4 | 33.6 | 32.0 | 34.2 | 35.9 | 32.3 | 87.4 | 101.4 | 78.1 | 40.4 |
| Cash conversion cycle (days) | 14.5 | 19.7 | 23.1 | 25.7 | 26.2 | 14.0 | -9.1 | 0.8 | 27.1 | 80.6 |
| Receivables turnover | 10.70 | 10.34 | 10.81 | 9.22 | 8.64 | 10.98 | 7.88 | 6.92 | 6.44 | 4.88 |
| Payables turnover | 10.60 | 10.87 | 11.41 | 10.67 | 10.15 | 11.29 | 4.18 | 3.60 | 4.67 | 9.04 |
| Inventory turnover | 24.52 | 20.35 | 17.12 | 17.96 | 18.31 | 27.90 | 11.42 | 7.38 | 7.53 | 7.90 |
| Asset turnover | 1.38 | 1.35 | 1.35 | 1.18 | 1.02 | 1.35 | 1.18 | 1.41 | 1.50 | 1.33 |
| Average receivables | $25.2M | $21.7M | $16.9M | $15.1M | $13.5M | $12.0M | $10.2M | $9.3M | $7.3M | $6.4M |
| Average payables | $10.8M | $8.4M | $6.2M | $5.1M | $4.3M | $4.5M | $5.8M | $4.6M | $2.6M | $1.4M |
| Average inventory | $4.7M | $4.5M | $4.1M | $3.0M | $2.4M | $1.8M | $2.1M | $2.3M | $1.6M | $1.6M |
| Intangibles / total assets | 28.0% | 19.1% | 19.6% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from VMD's annual financial statements (latest annual report filed March 4, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
VMD valuation and financial ratios
At the end of fiscal 2025 (December 31, 2025), Viemed Healthcare traded at 20.3 times earnings, against a 10-year median of 26.1. Based on the latest twelve months, the trailing P/E is 26.3 and the forward P/E is 18.3. Viemed Healthcare earned a return on equity of 10.9% and a return on invested capital of 11.1% in fiscal 2025. It ended the year with $15.9 million of debt and $13.5 million in cash and short-term investments, net debt of $2.4 million. It returned $13.2 million to shareholders: $0 in dividends and $13.2 million in share buybacks, 111% of free cash flow. The share count rose 7.7% from 37.9M to 40.8M over 9 years.
See the VMD income statement, the VMD chart for price history, or the VMD stock overview for the latest quote and news.
VMD key metrics FAQ
What is Viemed Healthcare's P/E ratio?
Viemed Healthcare's trailing P/E ratio is 26.3 based on the last twelve months of earnings (as of October 18, 2026), and its forward P/E is 18.3. At the end of fiscal 2025 it was 20.3, compared with a 10-year median of 26.1.
What is Viemed Healthcare's EV/EBITDA?
Viemed Healthcare's enterprise value was 5.9 times EBITDA at the end of fiscal 2025 (enterprise value $305.8 million, EBITDA $51.6 million); the current EV/EBITDA is 5.9.
What is Viemed Healthcare's return on equity?
Viemed Healthcare's return on equity (ROE) was 10.9% in fiscal 2025: net income of $14.9 million on average shareholders' equity of $136.5 million.
What is Viemed Healthcare's ROIC?
Viemed Healthcare's return on invested capital was 11.1% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does Viemed Healthcare have?
Viemed Healthcare had total debt of $15.9 million at the end of fiscal 2025, a debt-to-equity ratio of 0.11 and $2.4 million of net debt (0.05 times EBITDA).
Does Viemed Healthcare buy back its shares?
Yes. Viemed Healthcare spent $13.2 million on net share repurchases in fiscal 2025 Shares outstanding changed +0.0% over the year, to 40.8M..
What is Viemed Healthcare's free cash flow yield?
Viemed Healthcare generated $11.9 million of free cash flow in fiscal 2025, a free cash flow yield of 3.9% on its market value at year-end ($303.3 million).
What is Viemed Healthcare's current ratio?
Viemed Healthcare's current ratio was 1.18 at the end of fiscal 2025: current assets were 1.18 times current liabilities.